Close

Adverum Biotechnologies (ADVM) Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD

April 15, 2019 9:04 AM EDT Send to a Friend
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login